Ferric carboxymaltose in the treatment of iron deficiency in pediatric inflammatory bowel disease.

Transl Pediatr

Department of Gastroenterology, Queensland Children's Hospital, South Brisbane, Queensland, Australia.

Published: January 2019

Background: Iron deficiency (ID) with or without anemia is a common complication of pediatric inflammatory bowel disease (IBD), causing significant morbidity. Despite this, ID remains prevalent and undertreated, related in part to questions surrounding optimal formulation and route of administration. Ferric carboxymaltose (FCM) is a recent formulation of intravenous iron, allowing higher doses and rapid infusion times. This study aims to demonstrate the efficacy and safety of FCM in paediatric patients with IBD, and explore the differences between patients with active and quiescent disease.

Methods: Paediatric patients 6-18 years with IBD with iron deficiency (ID) or iron deficiency anemia (IDA) were treated prospectively with FCM at the Queensland Children's Hospital in Brisbane. Patients received FCM as a single dose of 15 mg/kg up to 1,000 mg over 15-20 min. Biochemical parameters measured prior to and approximately 8 weeks after the infusion were: hemoglobin (Hb), mean corpuscular volume (MCV), ferritin, and transferrin saturation (TS). C-reactive protein (CRP) was measured as a marker of co-existing inflammation. Resolution of anemia or ID was assessed following treatment, with adverse events captured.

Results: A total of 101 patients received infusions of FCM during the study period and were analysed, median age 14 (IQR 14-16) years. A total of 44% of patients underwent treatment for IDA, while 56% were for ID without anemia. Following FCM infusion, 64% of patients with IDA had resolution of anemia, with 81% showing resolution for ID without anemia. Elevation of CRP throughout the study period had no influence on resolution of IDA with FCM (P=0.68), but in patients with ID, patients with quiescent disease activity were more likely to have resolution of ID [odds ratios (ORs) 5.1; P=0.03].

Conclusions: Rapid, high dose FCM in children aged 6 and over is safe, well tolerated and efficacious for correction of ID. Replenishing iron in IBD is important and FCM improves our ability to meet this need.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382504PMC
http://dx.doi.org/10.21037/tp.2019.01.01DOI Listing

Publication Analysis

Top Keywords

iron deficiency
16
resolution anemia
12
fcm
9
patients
9
ferric carboxymaltose
8
pediatric inflammatory
8
inflammatory bowel
8
bowel disease
8
deficiency anemia
8
paediatric patients
8

Similar Publications

Background And Objective: Iron deficiency anemia (IDA) is a prominent cause of anemia adversely affecting the physical, mental, and social well-being of an individual. It is a major health concern and has impacted more than two billion people worldwide. It is necessary to implement programs to increase compliance rates for iron and folic acid (IFA) supplementation and educate individuals about anemia.

View Article and Find Full Text PDF

Objectives: Increasing research has shown that heavy metal as a neurotoxicant affects cognitive function across the lifespan. Nutritional status may modify susceptibility to heavy metal exposures, which further impacts cognition.

Methods: We conducted a comprehensive search for cross-sectional studies, longitudinal studies, case-control studies and clinical trials on the interaction between nutrient and heavy metal, as well as mixed heavy metal exposure, in relation to cognition across the lifespan.

View Article and Find Full Text PDF

Background: In Ethiopia, a school-based weekly iron and folic acid supplementation (WIFAS) program is being implemented to reduce burden of anemia in adolescent girls. While the program's impact on iron levels is well-studied, there is limited evidence on its effect on folate status.

Objective: The study was aimed at assessing the effect of the WIFAS on serum folate levels of school adolescent girls in Sidama Region, Southern Ethiopia.

View Article and Find Full Text PDF

Iron Deficiency Anaemia in a Stable Chronic Intestinal Failure Cohort: Prevalence, Associations and Outcomes.

Clin Nutr ESPEN

January 2025

Intestinal Failure Unit, Salford Royal NHS Foundation Trust, Salford M6 8HD, UK; School of Health Sciences, University of Manchester, Manchester M13 9PL, UK.

Background & Aims: Current estimates of the prevalence of iron deficiency anaemia (IDA) in patients with chronic intestinal failure (CIF) exceed those seen in general population, however, the studies to-date are limited with relatively small numbers of patients. The aim of the study was to determine the point prevalence of IDA in a large cohort of stable HPN-dependent adults managed by a specialist Intestinal Failure Unit.

Methods: This was a retrospective cohort study of HPN-dependent adults managed by a national UK IF Reference Centre between 01/01/2019 and 31/12/2019.

View Article and Find Full Text PDF

Iron deficiency anemia (IDA) is a prevalent nutritional deficiency problem. This study aimed to investigate the characteristics of Choerospondias axillaris polysaccharide-Fe (III) complex and its effect on IDA mice. CAP-Fe (III) complex was synthesized by co-thermal synthesis method with an iron content of 27.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!